GSK3B and early-onset autosomal dominant Alzheimer disease: This study showed that the synthetic compound aloisine A (compound 50, Table 5) is highly selective for GSK-3β (IC50 = 0.65 μM), but still GSK-3β was evaluated against cancers and neurodegenerative disorders such as Alzheimer’s disease but not for heart disease treatment [101].